Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ImmunoGen, Inc.    IMGN   US45253H1014

IMMUNOGEN, INC. (IMGN)

22
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Sales16,435,559,999,499,2111
Operating income (EBITDA)--68,4-66,9-54,1-48,0-34,0
Operating profit (EBIT)-73,3-73,0-71,5-59,5-64,6-51,0
Pre-Tax Profit (EBT)-73,3-72,8----
Net income-73,3-72,8-71,4-60,4-66,3-52,7
EPS ( $)-0,95-0,87-0,83-0,70-0,77-0,62
Dividend per Share ( $)------
Yield------
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Debt------
Finance-19514280,587,536,8
Operating income (EBITDA)--68,4-66,9-54,1-48,0-34,0
Leverage
(Debt/EBITDA)
------
Capital Expenditure2,903,778,185,516,251,50
Book Value Per Share (BVPS)-1,44 $0,88 $0,42 $1,49 $-0,02 $
Cash Flow per Share--0,72 $-0,63 $-0,64 $-0,43 $-
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 533 M$ -
Entreprise Value (EV) 452 M$ 445 M$
Valuation 2015e 2016e
PER (Price / EPS)
Capitalization / Revenue 5,36x 5,37x
EV / Revenue 4,55x 4,49x
EV / EBITDA -8,36x -9,29x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 14,9x 4,16x
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) -59,9% -65,1%
operating Leverage (Delta EBIT / Delta Sales) 0,25x -42,3x
Net Margin (Net Profit / Revenue) -60,8% -66,8%
ROA (Net Profit / Asset) -44,2% -
ROE (Net Profit / Equities) -113% -232%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   5,54% 6,30%
Cash Flow / Sales (Taux d'autofinancement) -55,4% -37,2%
Capital Intensity (Assets / Sales) 1,38x -
Financial Leverage (Net Debt / EBITDA) 1,49x 1,83x
EPS & Dividend
Dynamic quotes  
ON
| OFF